IO Pharmacodynamic Model Evaluation Platform

In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as our driving force, Medicilon has developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. We evaluate, CAR-T, TCR-T, CAR-NK, oncolytic virus, antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies), siRNA, AAV and other immunotherapy models for immunotherapy empowering the development of innovative therapies.

Syngeneic Models

The homologous tumor transplantation model tests the ability of model animals to use their own intact immune system to fight cancer and the therapeutic effect of immunotherapy.

The choices we offer you are:

Cancer Type	Cell Lines
Breast Cancer	4T1, EMT6, JC, C1271
Lung Cancer	LLC1(LLC1-luc), KLN205
Colon Cancer	CT26.WT, MC-38, CMT-93
Pancreatic Cancer	Panc 02
Renal Cancer	RENCA
Melanoma	B16-F10(B16-F10-luc), Clone-M3
Liver Cancer	H22, Hepa 1-6
Lymphoma	A20, EL4, P388D1, L5178-R, E.G7-OVA
Leukemia	C1498, L1210, WEHI-3
Myeloma	J558
Mastocytoma	P815

Flow cytometric typing of immune cells in model blood

Syngenic Models for detecting pharmacological effects of PD-1 drugs

PBMC Humanized Models

The humanized tumor mouse model possessing a partially reorganized human immune system is particularly effective for short-term research or high-throughput research.

The types of models currently available for Medicilon are:

Cancer Type	Cell Lines	Cancer Type	Cell Lines
Breast Cancer	HCC1954	Lymphoma	Raji, MOLM-13
Colon Cancer	HT29, Lovo, Ls174T	Myeloma	NCI-H929
Lung Cancer	NCI-H292, HCC827	Skin Cancer	A431
Leukemia (AML)	THP-1	Ovarian Cancer	OVCAR-3

Tumor growth and drug efficacy evaluation of PBMC humanized mouse lymphoma transplantation model

CD34+ HSC Humanized Models

Humanized mice transplanted with CD34+ human umbilical cord blood cells to reconstruct the human hematopoietic system are colonized in the mouse bone marrow, and continuously and stably produce various human hematopoietic cells and immune cells.

Medicilon’s currently available models are:

Cancer Type	Cell Lines
Brain Cancer	U-87 MG
Breast Cancer	HCC1954, MDA-MB-231, JIMT-1
Colon Cancer	HT29, LoVo
Gastric Cancer	NCI-N87
Lung Cancer	HCC827, NCI-H1975, NCI-H292, A549
Lymphoma	Raji, TMD8, MOLM-13
Myeloma	RPMI-8226, NCI-H929
Pancreatic Cancer	Capan-2
Skin Cancer	A431
Urinary Bladder Cancer	UM-UC-3

Tumorigenesis-of-breast-cancer-cells-in-hematopoietic-stem-cell-humanized-mice.jpg

Model Mice Produce Human-Derived Hematopoietic stem cells and Immune Cells
& Tumorigenesis of breast cancer cells in hematopoietic stem cell humanized mice

Orthotopic Model

The xenogeneic orthotopic tumor transplantation model can allow studies that assess the interaction of tumor cells and the organ microenvironment between the surrounding stroma so that tumor growth can be monitored when evaluating drug efficacy.

Cancer Type	Orthotopic Model	Orthotopic Model (Luc Cell Line)
Brain Cancer	U87-MG	U87-MG-luc
Lung cancer	NCI-H1650, A549, NCI-H1975, NCI-H460, LLC1	A549-luc,LLC1-luc, NCI-H1975-luc
Colon cancer	HCT-116, LoVo	HT29-luc
Gastric cancer	Hs 746T
Pancreas cancer	Mia-Paca 2	Mia-Paca ;2-luc
Breast cancer	MDA-MB-231	4T1-luc
Ovarian cancer	SK-OV-3	SK-OV-3-luc
Prostate Cancer	PC3	PC-3-luc
Renal Cancer	A498
Bladder Cancer	UM-UC-3
Melanoma		B16-F10-luc
Liver Cancer	H22
Bone Cancer

At present, Medicilon has mature orthotopic transplantation technology, including orthotopic brain, orthotopic liver, orthotopic lung, orthotopic tibia marrow cavity and orthotopic intravesical transplantation.

Orthotopic brain transplantation

Lung metastasis model

Tibia bone marrow cavity orthotopic transplantation

Orthotopic ovarian cancer transplantation

PDX Models

The human tumor transplantation model PDX retains the characteristics of the patient’s tumor tissue and is more clinically relevant. Combined with humanized mice, it can establish an ideal tumor immunotherapy evaluation model.

Medicilon has now developed:

Cancer Type	Cell Lines
Colon Cancer	PDXM-008C, PDXM-016C, PDXM-020C, PDXM-021C, PDXM-057C, PDXM-060C, PDXM-075C, PDXM-076C, PDXM-087C, PDXM-104C, PDXM-095C, PDXM-084C, PDXM-072C, PDXM-069C, PDXM-057C, PDXM-015C, PDXM-002C,
Lung Cancer	PDXM-054Lu, PDXM-050Lu, PDXM-047Lu, PDXM-053Lu, PDXM-028Lu,
Gastric Cancer	PDXM-092Ga, PDXM-091Ga,
Breast Cancer	PDXM-201B, PDXM-202B, PDX-203B
Liver Cancer	PDXM-211Li, PDXM-212Li
Pancreas Cancer	PDXM-221Pa, PDXM-222Pa
Bladder Cancer	PDXM-231U, PDXM-232U
Lymphoma	PDXM-241Ly, PDXM-242Ly

Medicilon’s PDX model research includes molecular level genotyping and tumor model pharmacological efficacy evaluation services, providing a highly predictive model for the study of clinical efficacy.

TMB gene mutation load detection and model tumor growth curve in PDX model of lung cancer

FAQs

What is Car-T Cell Therapy?

Chimeric antigen receptor T cell (CAR-T) refers to the transfer of genetic material with specific antigen recognition domain and T cell activation signal into T cells through gene modification technology, so that T cells can be transformed into T cells. It is activated by directly binding to specific antigens on the surface of tumor cells, directly killing tumor cells by releasing perforin, granzyme B, etc., and at the same time, it also recruits human endogenous immune cells to kill tumor cells by releasing cytokines, so as to achieve therapeutic effect. It can also form immune memory T cells to obtain a specific long-acting mechanism against liver tumors.
Preclinical Research Animal Models of Commonly Used CAR-T Cell Products

a) Syngeneic Mouse model with complete immune system
    Burdened murine tumor
    Mouse-derived CAR-T cells for detection of on-target and off-target toxicity
b) Transgenic Mouse with normal immune system
    Express human TAA
    Mouse-derived cell
    Proof-of-concept study
c) Xenograft mouse model (Human Xenograft Mouse)
    Immunodeficient mice
    Human-derived tumor
    Direct proof-of-concept studies
d) Humanized Immune System mice (Humanized Immune System mice, HIS mice)